{
  "docId": "019de075-746f-7643-8ae7-19646171e75b",
  "docSlug": "e49fd8f0d5e7ac656caa3720c9a74f92",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 28,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a structured grid layout to present key value drivers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-746f-7643-8ae7-19646171e75b/4",
  "deckHref": "/decks/019de075-746f-7643-8ae7-19646171e75b",
  "deckJsonHref": "/decks/019de075-746f-7643-8ae7-19646171e75b.json",
  "deckAnchorHref": "/decks/019de075-746f-7643-8ae7-19646171e75b#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.822,
        "x": 0.089,
        "y": 0.248
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "718c06df-7058-4c65-bff0-de8f739e38e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.822,
        "x": 0.089,
        "y": 0.36
      },
      "kind": "list",
      "text": "Indications with significant unmet medical need & large market opportunities; Team with virology expertise and proven track record; Broad portfolio of internally discovered assets with distinct MOAs; Lead HBV compound – imdusiran (AB-729) RNAi therapeutic in multiple Phase 2a combination clinical trials; Strong financial position; Patented LNP technology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91c20943-6d75-489f-8ce9-89cffb842f14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.822,
        "x": 0.089,
        "y": 0.6
      },
      "kind": "list",
      "text": "Focused on developing functional cure for HBV and oral pan-coronavirus therapeutics; Discovered, developed & commercialized multiple drugs; RNAi therapeutic, PD-L1 inhibitor, RNA destabilizer, Mpro inhibitor, Nsp12 polymerase inhibitor; Data shows imdusiran is generally safe and well-tolerated and has shown meaningful suppression of HBsAg while on- or off-treatment; Cash runway into Q1 2025; Receiving licensing royalties arising from Alnylam’s Onpattro and seeking damages for Moderna & Pfizer/BioNTech COVID-19 vaccine sales",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0a00905-f59e-48e4-8750-c6fbd0d4cc89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.42,
        "x": 0.145,
        "y": 0.925
      },
      "kind": "paragraph",
      "text": "MOA: Mechanism of Action | PD-L1: Programmed death-ligand 1 | Mpro: Main protease | NSP12: Non-structural protein | HBsAg: Hepatitis B surface antigen",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15c82ccc-8bfa-434b-8e7c-4e273ef4ef0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.083,
        "w": 0.395,
        "x": 0.076,
        "y": 0.056
      },
      "kind": "title",
      "text": "Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72a41169-6ede-428f-961a-5a4c8fd02483",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "0ca6384b-3924-411e-a348-521ecec4b436",
      "evidence": "This slide serves as a high-level overview of the investment highlights, summarizing key points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}